Long-term Safety Study of MP-513 as Monotherapy or in Combination With Oral Antihyperglycaemic Agent in Japanese Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2018
At a glance
- Drugs Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 01 Apr 2018 Results of a pooled analysis from NCT01301833 and NCT02314637 studies, published in the Diabetes Therapy.
- 10 Jun 2017 Biomarkers information updated
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.